ArticleIntensive care medicine2011
Repeated measurements of endothelin-1 precursor peptides predict the outcome in community-acquired pneumonia.
Article in Intensive care medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03651635 (To Assess and Validate the Use of MR-proADM and the CT-proET-1/MR-proADM Ratio as Prognostic Markers During the First 7 Days of ICU Treat-ment), which is not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
To Assess and Validate the Use of MR-proADM and the CT-proET-1/MR-proADM Ratio as Prognostic Markers During the First 7 Days of ICU Treat-ment
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis.Critical care (London, England) · 2012Pooled it
- Lack of value of midregional pro-adrenomedullin and C-terminal pro-endothelin-1 for prediction of severe bacterial infections in infants with fever without a source.European journal of pediatrics · 2013Trial
- Predictive value of critical illness scores for outcomes of patients with community-acquired pneumonia: analysis of critical care data from the MIMIC-IV database.BMC pulmonary medicine · 2026Article
- Cardiovascular Complications in Community-Acquired Pneumonia.Microorganisms · 2022Review
- Joint Modeling of Repeated Measurements of Different Biomarkers Predicts Mortality in COVID-19 Patients in the Intensive Care Unit.Biomarker insights · 2022Article
- Biomarkers in Community-Acquired Pneumonia (Cardiac and Non-Cardiac).Journal of clinical medicine · 2020Review
- Hot topics and current controversies in community-acquired pneumonia.Breathe (Sheffield, England) · 2019Review
- Managing CAP in the ICU.Current infectious disease reports · 2015Article
- Optimizing triage and hospitalization in adult general medical emergency patients: the triage project.BMC emergency medicine · 2013Observational
- Serum cortisol predicts death and critical disease independently of CRB-65 score in community-acquired pneumonia: a prospective observational cohort study.BMC infectious diseases · 2012Article
- Year in review in Intensive Care Medicine 2011. II. Cardiovascular, infections, pneumonia and sepsis, critical care organization and outcome, education, ultrasonography, metabolism and coagulation.Intensive care medicine · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeExcessive activation of the endothelium is associated with adverse outcomes in patients with systemic infections. Endothelium-associated peptides, such as endothelin-1 (ET-1), correlate closely with endothelial activation, and therefore serve as surrogate biomarkers. Our aim was to investigate precursor peptides of endothelin-1 (proET1) on admission and during follow-up on days 3, 5 and 7 in a prospective cohort of 925 patients with community-acquired pneumonia.
methodsWe investigated the association of initial and follow-up proET1 and other prohormone levels with 30-day mortality and ICU admission in proportional Cox regression models with time-varying covariates adjusted for the pneumonia-severity-index (PSI), and calculated reclassification statistics.
resultsThe mortality rate and ICU admission rate were 5.4% (95% CI 3.9-6.8%) and 9.0% (95% CI 7.1-10.8%). ProET1 levels on admission and changes from baseline to day 3 were significant mortality predictors with adjusted hazard ratios of 10.5 (95% CI 2.9-38.6) and 28.4 (95% CI 7.0-115.1). Initial proET1 levels improved the PSI in reclassification statistics (net reclassification improvement of 0.29, p<0.0001) and in c-statistics (from 0.79 to 0.83, p<0.01). Changes of proET1 on day 3 improved the c-statistic of the combined model of PSI and initial proET1 from 0.80 to 0.85 (p<0.01) and reclassification tables demonstrated a significant improvement (net reclassification improvement 0.44, p<0.0001). Similar significant results were found for the risk for ICU admission.
conclusionsIn community-acquired pneumonia, ET-1 precursor peptides on admission and changes from baseline to day 3 were independent predictors for mortality and ICU admission, and significantly improved the PSI. If verified in intervention studies, monitoring of proET1 may be helpful for endothelium targeting therapies and for risk stratification complementary to other prohormones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.